Search Results

5 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 48

    The in vitro biological assessment of a novel hybrid tobacco product and comparison with a cigarette smoke

    BREHENY D.; ADAMSON J.; AZZOPARDI D.; BAXTER A.; BISHOP E.; CARR T.; CROOKS I.; HEWITT K.; JAUNKY T.; LARARD S.; LOWE F.; OKE O.; TAYLOR M.; SANTOPIETRO S.; THORNE D.; ZAINUDDIN B.; GAҪA M.; LIU C.; MURPHY J.; PROCTOR C.
    British American Tobacco (Investments) Limited, R&D, Southampton, U.K.
    Cigarette smoking is a risk factor for many diseases including cardiovascular disease, lung disease, and cancer. Recently there has been an increase in the development and consumer acceptance of novel nicotine and tobacco products including tobacco ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 49

    In vitro assessment of a novel prototype e-cigarette

    DALRYMPLE A.; JAUNKY T.; TERRY A.; BOZHILOVA S.; BAXTER A.; ADAMSON J.; HEWITT K.; TAYLOR M.; CARR T.; GAÇA M.
    British American Tobacco (Investments) Limited, R&D, Southampton, U.K.
    E-cigarettes have rapidly increased in popularity over the last decade and there is a growing consensus that e-cigarettes hold great potential for reducing the risk associated with cigarette smoking. In this study, the responses of a novel prototype e ...
  3. TSRC, Tob. Sci. Res. Conf., 2011, 65, abstr. 12

    An examination of the biological effects of reduced toxicant prototype cigarettes using in vitro models of smoking-related diseases.

    FEARON I.M.; TAYLOR M.; CARR T.; COCKCROFT N.; SMITH G-F.; HEWITT K.; HASWELL L.; BISHOP E.; PHILLIPS G.
    British American Tobacco, GR&D, Southampton, UK
    INTRODUCTION: A potential approach to reduce the harm associated with cigarette smoking is to reduce smoke toxicant levels. In vitro models of smoking-related diseases may provide screening tools for cigarettes with altered smoke toxicant levels and data ...
  4. TSRC, Tob. Sci. Res. Conf., 2011, 65, abstr. 41

    The use of endpoints in in vitro models of cardiovascular disease exposed to human smokers? serum as potential biomarkers of smoking-related cardiovascular disease.

    FEARON I.M.; MCQUILLAN K.; TAYLOR M.; CARR T.; MAYLAND O.; HEWITT K.; LUETTICH K.; LOWE F.J.
    British American Tobacco, GR&D, Southampton, UK
    Introduction: Cigarette smoking is a recognised cardiovascular disease (CVD) risk factor. In vitro models, in which cells are exposed to particulate or aqueous cigarette smoke extracts, are used to study CVD mechanisms and to examine the role of smoking ...